-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
An international research team led by scientists from the Hong Kong University of Science and Technology (HKUST) has developed a new strategy that uses whole-brain genome editing technology to reduce Alzheimer's disease (AD) pathology in genetically modified AD mouse models
In China alone, it is estimated that more than 500,000 patients suffer from hereditary AD-familial Alzheimer's disease (FAD), which is a congenital AD that is highly correlated with family history
The use of genome editing technology as a strategy to treat diseases caused by genetic mutations (such as FAD) has great potential
Recently, a research team led by Professor Ye Yuru of the Hong Kong University of Science and Technology has developed a new genome editing system that can not only penetrate the blood-brain barrier, but also deliver optimized genome editing tools to the entire brain
At the same time, the research team also found that in the mouse model, the level of amyloid is still very low 6 months after treatment (about 1/3 of their normal lifespan), indicating this single genome editing Strategy has a lasting impact
Professor Ye said: "This is the first effective brain genome editing technology that can relieve the symptoms of Alzheimer's disease in the entire brain.
This research is the result of joint efforts of scientists from the Hong Kong University of Science and Technology, California Institute of Technology and Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences
Original search:
Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice
DOI 10.